Leuprolide mesylate clinical trials
A product of Leuprolide; its studies count on that page too.
How each study uses leuprolide mesylate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 25 May 2021 · CAMCEVI KIT · NDA 211488 (FDA, Drugs@FDA)
- European Union
- 24 May 2022 · Camcevi · EMEA/H/C/005034 (EMA; as Leuprolide)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Leuprolide Mesylate
- 2
Studies by the year they started
3 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Foresee Pharmaceuticals Co., Ltd. (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (1)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Leuprolide
Studies
Open first, then newest update. How each study uses leuprolide mesylate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.CompletedPhase 3Changchun GeneScience Pharmaceutical Co., Ltd.NCT06984159Written as Leuprolide Injectable Emulsion (CAMCEVI®)
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate CancerCompletedPhase 3Foresee Pharmaceuticals Co., Ltd.NCT03261999Written as Leuprolide Mesylate
- Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate CarcinomaCompletedPhase 3Foresee Pharmaceuticals Co., Ltd.NCT02234115Written as Leuprolide Mesylate
Codes
What other systems call leuprolide mesylate · ClinicalTrials.gg INT015647
- UNII (FDA) 8E3C3C493WLEUPROLIDE MESYLATEConfirmed FDA, Wikidata
- RxNorm 2595041One source FDA
- Wikidata Q27270242leuprolide mesylateConfirmed FDA, Wikidata
- NCI Thesaurus C190727Leuprolide MesylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8E3C3C493W | LEUPROLIDE MESYLATE | Confirmed FDA, Wikidata |
| RxNorm | 2595041 | — | One source FDA |
| Wikidata | Q27270242 | leuprolide mesylate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190727 | Leuprolide Mesylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.